- Home
- CERO vs LDWY Comparison
CERO vs LDWY Comparison
Compare CERO & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- LDWY
- Stock Information
- Founded
- CERO 2017
- LDWY 1990
- Country
- CERO United States
- LDWY United States
- Employees
- CERO N/A
- LDWY N/A
- Industry
- CERO
- LDWY Advertising
- Sector
- CERO
- LDWY Consumer Discretionary
- Exchange
- CERO Nasdaq
- LDWY Nasdaq
- Market Cap
- CERO 9.6M
- LDWY 9.2M
- IPO Year
- CERO N/A
- LDWY 1991
- Fundamental
- Price
- CERO $8.25
- LDWY $5.13
- Analyst Decision
- CERO Strong Buy
- LDWY
- Analyst Count
- CERO 2
- LDWY 0
- Target Price
- CERO $45.00
- LDWY N/A
- AVG Volume (30 Days)
- CERO 40.2K
- LDWY 3.1K
- Earning Date
- CERO 08-29-2025
- LDWY 09-02-2025
- Dividend Yield
- CERO N/A
- LDWY N/A
- EPS Growth
- CERO N/A
- LDWY N/A
- EPS
- CERO N/A
- LDWY N/A
- Revenue
- CERO N/A
- LDWY $42,183,000.00
- Revenue This Year
- CERO N/A
- LDWY N/A
- Revenue Next Year
- CERO N/A
- LDWY N/A
- P/E Ratio
- CERO N/A
- LDWY N/A
- Revenue Growth
- CERO N/A
- LDWY 425.12
- 52 Week Low
- CERO $6.71
- LDWY $3.02
- 52 Week High
- CERO $895.40
- LDWY $5.60
- Technical
- Relative Strength Index (RSI)
- CERO 49.24
- LDWY 53.53
- Support Level
- CERO $8.07
- LDWY $4.94
- Resistance Level
- CERO $8.90
- LDWY $5.20
- Average True Range (ATR)
- CERO 0.40
- LDWY 0.16
- MACD
- CERO 0.11
- LDWY -0.00
- Stochastic Oscillator
- CERO 59.38
- LDWY 84.44
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.